Notice of Correction, 44811 [2014-18087]
Download as PDF
<![CDATA[
Federal Register / Vol. 79, No. 148 / Friday, August 1, 2014 / Notices
Please make sure that the FDA post
office box number (P.O. Box 979107) is
written on the check, bank draft, or
postal money order.
Wire transfer payment may also be
used. Please reference your unique user
fee ID number when completing your
transfer. The originating financial
institution may charge a wire transfer
fee. Please ask your financial institution
about the fee and add it to your payment
to ensure that your fee is fully paid. The
account information for wire transfers is
as follows: New York Federal Reserve
Bank, U.S. Department of the Treasury,
TREAS NYC, 33 Liberty St., New York,
NY 10045, Acct. No.: 75060099, Routing
No.: 021030004, SWIFT: FRNYUS33,
Beneficiary: FDA, 8455 Colesville Rd.,
14th Floor, Silver Spring, MD 20993–
0002.
Application fees can also be paid
online with an electronic check (ACH).
FDA has partnered with the U.S.
Department of the Treasury to use
Pay.gov, a Web-based payment
application, for online electronic
payment. The Pay.gov feature is
available on the FDA Web site after the
user fee ID number is generated.
The tax identification number of FDA
is 53–0196965.
B. Establishment and Product Fees
FDA will issue invoices for
establishment and product fees for FY
2015 under the new fee schedule in
August 2014. Payment will be due on
October 1, 2014. FDA will issue
invoices in November 2015 for any
products and establishments subject to
fees for FY 2015 that qualify for fee
assessments after the August 2014
billing.
Dated: July 25, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014–18113 Filed 7–31–14; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
tkelley on DSK3SPTVN1PROD with NOTICES
Notice of Correction
The National Institutes of Health NIH
published in the Federal Register on
July 18, 2014 a notice titled ‘‘Proposed
Collection; 60-Day Comment Request; A
Generic Submission for Formative
Research, Pre-Testing, Stakeholder
Measures and Advocate Forms at NCI’’
[79 FR 42023]. The notice contained an
incorrect email address for Kelley
Landy, Acting Director of the Office of
VerDate Mar<15>2010
22:09 Jul 31, 2014
Jkt 232001
Advocacy Relations. The correct email
address is kelley.landy@nih.gov.
Dated: July 28, 2014.
Cynthia Chaves,
NIH Federal Register Liaison.
[FR Doc. 2014–18087 Filed 7–31–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Submission for OMB Review; 30-Day
Comment Request; Recruitment and
Screening for the Insight Into
Determination of Exceptional Aging
and Longevity (IDEAL) Study
Under the provisions of
Section 3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Institutes of Health (NIH), has submitted
to the Office of Management and Budget
(OMB) a request for review and
approval of the information collection
listed below. This proposed information
collection was previously published in
the Federal Register on April 2, 2014,
Vol. 79, page 18569 and allowed 60days for public comment. No public
comments were received. The purpose
of this notice is to allow an additional
30 days for public comment. The
National Institute on Aging (NIA),
National Institutes of Health, may not
conduct or sponsor, and the respondent
is not required to respond to, an
information collection that has been
extended, revised, or implemented on or
after October 1, 1995, unless it displays
a currently valid OMB control number.
Direct Comments to OMB: Written
comments and/or suggestions regarding
the item(s) contained in this notice,
especially regarding the estimated
public burden and associated response
time, should be directed to the: Office
of Management and Budget, Office of
Regulatory Affairs, OIRA_submission@
omb.eop.gov or by fax to 202–395–6974,
Attention: NIH Desk Officer.
Comment Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 30-days of the date of
this publication.
FOR FURTHER INFORMATION CONTACT: To
obtain a copy of the data collection
plans and instruments or request more
information on the proposed project
contact: Luigi Ferrucci, M.D., Ph.D., NIA
Clinical Research Branch, Harbor
Hospital, 5th Floor, 3001 S. Hanover,
Baltimore, MD 21225 or call non-tollfree number (410) 350–3936 or Email
your request, including your address to:
Ferruccilu@grc.nia.nih.gov. Formal
SUMMARY:
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
44811
requests for additional plans and
instruments must be requested in
writing.
Proposed Collection: Recruitment and
Screening for the Insight into
Determination of Exceptional Aging and
Longevity (IDEAL) Study (OMB#: 0925–
0631). National Institute on Aging
(NIA), National Institutes of Health
(NIH).
Need and Use of Information Collection
Longevity combined with good health
and functionality at the end of life
represents a common goal. Although
research has examined correlates of long
life and functional decline, we still
know relatively little about why certain
individuals live in excellent health into
their eighties while others succumb to
failing health at much younger ages.
Understanding the mechanisms
important to ideal aging may provide
new opportunity for health promotion
and disability prevention is this rapidly
growing segment of the population.
The purpose of IDEAL (Insight into
the Determinants of Exceptional Aging
and Longevity) is to recruit into the
Baltimore Longitudinal Study on Aging
(BLSA) exceptionally long lived and
healthy individuals and to learn what
makes them so resilient and resistant to
disease and disability, and to identify
potential interventions that may
contribute to the IDEAL condition. By
enrolling the IDEAL cohort in the BLSA
their biologic, physiologic, behavioral
and functional characteristics will be
evaluated using the same methods used
with the current cohort who will serve
as a type of control group. The first aim
is to identify factors and characteristics
that distinguish IDEAL from non-IDEAL
individuals. We intend to compare the
two groups to identify factors that
discriminate IDEAL aging from nonIDEAL aging individuals. The second
aim is to identify physiological,
environmental and behavioral
characteristics that are risk factors for
losing the IDEAL condition over several
years or longer. We postulate that the
mechanisms of extreme longevity
probably differ from those associated
with delay or escape from disease and
disability. As is customary in the BLSA,
we plan to follow this cohort for life
with yearly visits. This is a request for
OMB to approve a reinstatement with
change of Recruitment and Screening
for the Insight into Determination of
Exceptional Aging and Longevity
(IDEAL) Study for 3 years.
OMB approval is requested for 3
years. There is no annualized cost to
respondents. The total estimated
annualized burden hours are 333.
E:\FR\FM\01AUN1.SGM
01AUN1
]]>Agencies
[Federal Register Volume 79, Number 148 (Friday, August 1, 2014)]
[Notices]
[Page 44811]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-18087]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Notice of Correction
The National Institutes of Health NIH published in the Federal
Register on July 18, 2014 a notice titled ``Proposed Collection; 60-Day
Comment Request; A Generic Submission for Formative Research, Pre-
Testing, Stakeholder Measures and Advocate Forms at NCI'' [79 FR
42023]. The notice contained an incorrect email address for Kelley
Landy, Acting Director of the Office of Advocacy Relations. The correct
email address is kelley.landy@nih.gov.
Dated: July 28, 2014.
Cynthia Chaves,
NIH Federal Register Liaison.
[FR Doc. 2014-18087 Filed 7-31-14; 8:45 am]
BILLING CODE 4140-01-P
